Abstract:Aim Duchenne muscular dystrophy is a progressive muscle‐wasting disease caused by mutations in the dystrophin gene. Despite progress in dystrophin‐targeted gene therapies, it is still a fatal disease requiring novel therapeutics that can be used synergistically or alternatively to emerging gene therapy. Defective autophagy and disorganized microtubule networks contribute to dystrophic pathogenesis, yet the mechanisms by which microtubule alterations regulate autophagy remain elusive. The present study was designed to uncover possible mechanisms underpinning the role of microtubules in regulating autophagy in dystrophic mice. Methods Mdx mice were also supplemented with Tubastatin A, a pharmacological inhibitor of histone deacetylase 6, and pathophysiology was assessed. Mdx mice with a genetic deletion of the Nox‐2 scaffolding subunit p47phox were used to assess redox dependence on tubulin acetylation. Results Our data show decreased acetylation of α‐tubulin with enhanced histone deacetylase 6 expression. Tubastatin A increases tubulin acetylation and Q‐SNARE complex formation but does not alter microtubule organization or density, indicating improved autophagosome–lysosome fusion. Tubastatin A increases the acetylation of peroxiredoxin and protects it from hyper‐oxidation, hence modulating intracellular redox status in mdx mice. Tubastatin A reduces muscle damage and enhances force production. Genetic down regulation of Nox2 activity in the mdx mice promotes autophagosome maturation but not autolysosome formation. Conclusion Our data highlight that autophagy is differentially regulated by redox and acetylation in mdx mice. By improving autophagy through promoting tubulin acetylation, Tubastatin A decreases the dystrophic phenotype and improves muscle function, suggesting a great potential for clinical translation and treating dystrophic patients.

[Histone Deacetylase 6: the Key Regulator of Misfolded Proteins].

Histone deacetylase 6 in cancer

Histone deacetylase 6 regulates cytotoxic α-synuclein accumulation through induction of the heat shock response.

HDAC6-mediated Hsp90 deacetylation reduces aggregation and toxicity of the protein alpha-synuclein by regulating chaperone-mediated autophagy

The Cytoplasmic Deacetylase HDAC6 is Required for Efficient Oncogenic Tumorigenesis

HAP40 is a conserved central regulator of Huntingtin and a specific modulator of mutant Huntingtin toxicity

Histone deacetylase 6's function in viral infection, innate immunity, and disease: latest advances

The Role of HDAC6 in Autophagy and NLRP3 Inflammasome

A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity

Histone deacetylase 6 structure and molecular basis of catalysis and inhibition

Metabolic regulation of cytoskeleton functions by HDAC6-catalyzed α-tubulin lactylation

An HDAC6-dependent Surveillance Mechanism Suppresses Tau-Mediated Neurodegeneration and Cognitive Decline

Histone deacetylase 6 inhibition promotes microtubule acetylation and facilitates autophagosome–lysosome fusion in dystrophin‐deficient mdx mice

Histone deacetylase 7 activates 6-phosphogluconate dehydrogenase via an enzyme-independent mechanism that involves the N-terminal protein-protein interaction domain

Curriculum vitae of HDAC6 in solid tumors

HDAC6 mediates tumorigenesis during mitosis and the development of targeted deactivating agents

Structure‐Based Discovery of A Small Molecule Inhibitor of Histone Deacetylase 6 (HDAC6) that Significantly Reduces Alzheimer's Disease Neuropathology

Inhibition of HDAC6 Increases Acetylation of Peroxiredoxin1/2 and Ameliorates 6-OHDA Induced Dopaminergic Injury

Histone deacetylase complexes: Structure, regulation and function

A novel insight into neurological disorders through HDAC6 protein–protein interactions

Histone deacetylase 6 and cytoplasmic linker protein 170 function together to regulate the motility of pancreatic cancer cells